GLP-1 Weight Loss Drug Use Rising in U.S., Gallup Poll Finds

Approximately 1 in 8 U.S. adults reports having ever taken a GLP-1 receptor agonist, with current usage rates reaching roughly 11% of the population, according to recent data from Gallup. These medications, originally approved for type 2 diabetes management, have seen a significant surge in demand for chronic weight management, reshaping the pharmaceutical landscape and public health discourse.

Current Prevalence of GLP-1 Usage

Data released by Gallup in late 2024 indicates that the adoption of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide and tirzepatide—has become widespread among American adults. While 11% of respondents report currently using these medications, an additional 2% indicate they have used them in the past but have since stopped.

The trend reflects a broader shift in how obesity and metabolic health are being treated in clinical settings. According to the U.S. Food and Drug Administration (FDA), these drugs mimic hormones that target areas of the brain that regulate appetite and food intake, leading to significant weight reduction when combined with lifestyle modifications.

Factors Driving Increased Utilization

The rise in usage is tied to expanded clinical indications and increased visibility. Initially marketed for glycemic control in type 2 diabetes, drugs like Wegovy and Zepbound received FDA approval specifically for chronic weight management in patients with obesity or overweight conditions accompanied by weight-related comorbidities.

Public interest has been further fueled by social media discourse and celebrity endorsements, though medical professionals emphasize that these drugs are prescription-only treatments requiring ongoing physician supervision. The American Medical Association (AMA) continues to categorize obesity as a complex, chronic disease, which has helped shift the focus toward pharmacological interventions as a standard of care for many patients.

Clinical Considerations and Safety Monitoring

Despite the popularity of GLP-1s, the medical community maintains strict guidelines regarding their use. The National Institutes of Health (NIH) notes that patients must be evaluated for specific risks, including potential gastrointestinal side effects like nausea, vomiting, and diarrhea.

Furthermore, because these medications are often intended for long-term use, researchers are monitoring outcomes related to sustainable weight maintenance after discontinuation. Clinical trials have demonstrated that weight regain is common once the medication is stopped, reinforcing the necessity of a comprehensive approach to treatment that includes nutritional counseling and physical activity.

Comparison of Patient Demographics

Gallup’s findings highlight distinct patterns in who is accessing these treatments. Usage is notably higher among individuals with higher self-reported body mass indices (BMI) and those with existing cardiovascular or metabolic concerns.

As the market for these drugs continues to expand, the focus for healthcare systems remains on ensuring equitable access while managing supply chain constraints that have periodically affected the availability of specific dosages for patients with diabetes and obesity.